PHARMACOTHERAPY OF MULTIPLE SCLEROSIS: TREATMENT OF EXACERBATIONS, IMMUNOMODULATORY THERAPY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, treatment of multiple sclerosis is one of the most serious problems of modern medicine. The article discusses the problems of pharmacotherapy of patients during exacerbation, tactics of conversion from first-line drugs to second-line drugs, the use of multiple sclerosis disease modifying drugs.

Full Text

Restricted Access

About the authors

M. A Kurapov

SBHCI Samara Regional Clinical Hospital n.a. V.D. Seredavin

Email: kurapovmichael@mail.ru
neurologist at the Center of Demyelinating Diseases and Multiple Sclerosis of the Samara region Samara

Ya. V Vlasov

FSBEI HE “Samara State Medical University" of RMH

Department of Neurology and Neurosurgery Samara

References

  1. Аутоиммунные заболевания в неврологии / Под ред. И.А. Завалишина, М.А. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина, А.В. Переседовой Клиническое руководство. М., 2014. Т. 1. 400 с.
  2. Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. Руководство для врачей. М., 2012. 272 с.
  3. Тарасова С.В., Курапов М. А. Опыт применения препаратов тиоктовой кислоты в комплексном лечении пациентов с обострением рассеянного склероза. Фарматека. 2014;19:59-63.
  4. Рассеянный склероз. Клиническое руководство / Под ред. Е.И. Гусева, И.А. Завалишина, А.Н. Бойко. М., 2011. 528 с.
  5. Ведение больных рассеянным склерозом. Методические рекомендации / Под ред. Н.Н. Спирина, А.Н. Бойко, И.О. Степанова, Т.Е. Шмидт. Ярославль-Москва, 2015. 68 с.
  6. Miller D.M., Weinstock-Guttman B., Bethoux F., Lee J.C., Beck G., Block V., Durelli L., LaMantia L., Barnes D., Sellebjerg F., Rudick R.A. A metaanalysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Multiple Sclerosis. 2000;6:267-73.
  7. Berkovich R. Treatment of Acute Relapses in Multiple Sclerosis. Neurotherapeutics. 2013;10(1):97-105.
  8. Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J. Neurology. 2008;255(Suppl. 6):36-42.
  9. Cortese I., Chaudhry V., So Y.T., Cantor F., Cornblath D.R., Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294-300.
  10. O'Connor P.W., Goodman A., Willmer-Hulme A.J., Libonati M.A., Metz L., Murray R.S., Sheremata W.A., Vollmer T.L., Stone L.A., Natalizumab. Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62:2038-43.
  11. Henze T., Rieckmann P., Toyka K.V. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therap Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol. 2006;56(2):78-105.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies